Dosing JAK Inhibitors in Patients With Myelofibrosis

Opinion
Video

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
4 experts in this video
4 experts in this video
Photo of a man wearing glasses and a suit in front of a blue background
Related Content